Just say “Ayoko Muna” to this upcoming Bill Gates’ New, Untested SKYCovion Vaccine “… which seems to have been specifically intended for deployment in developing nations.”
UK regulators who are funded by Bill Gates have granted approval to a recently developed and untested COVID vaccine, financed by Bill Gates, which seems to have been specifically intended for deployment in developing nations.
The SKYCovion vaccine was awarded regulatory approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) despite the lack of testing. MHRA is primarily funded by the the Bill & Melinda Gates Foundation. SKYCovion, developed in South Korea, received substantial funding from Bill Gates.
It incorporates a section of the SARS-CoV-2 virus spike protein along with an “adjuvant.” This new, untested vaccine consists of self-assembled nanoparticles and is enhanced with GSK’s AS03 adjuvant technology.
Manufactured (By SK Bioscience Co., Ltd. Collaboration with the International Vaccine Institute, GlaxoSmithKline and Coalition for Epidemic Preparedness Innovations), and approved for use in S.Korea. (Link #1 and Link #2)
Says Status is Active but Not Yet Recruiting. Did not specify how many participants from each country but there have been 2 trials made here already. (Link #3)
Results according to GSK: “SK bioscience conducted a Phase III clinical trial in 4,037 adults over 18-year-old across 6 countries (Thailand, Vietnam, New Zealand, Ukraine, the Philippines and South Korea). The vaccine candidate demonstrated superior neutralizing antibody titres over AstraZeneca’s Vaxzevria™ (control vaccine), a currently authorized COVID-19 vaccine. SKYCovione™ vaccine candidate showed a clinically favorable safety profile. …
The results of the Phase III clinical trial show a superior neutralizing antibody response of SKYCovione™ against SARS-CoV-2 parental strain, 2.93 times that of a control vaccine 2 weeks after the second dose.” (link #3)
According to Korea Biomedical Review last Oct.2022 (Independent): (Link #4)
– “Although SK Bioscience argues that the speed of inoculation is getting faster, industry watchers say the company is fighting an uphill battle.”
– No WHO EUL approval yet.
출처 : KBR(https://www.koreabiomed.com)
Any Gain-Of-Function research though? Hmmm … Ukraine + New Zealand + Taiwan + Vietnam … Please, not in my country.
You can put the hyperlink right ‘underneath’ the related text so you don’t have to reference Link#1, #2, etc.. You’ll need to edit your IMO from the back-end (Security feature). Shade the texts you want hyperlinked first then just click on the “link“ button, box shows up, then paste the link into the box field then click “Add Link“ button. Like this: Hyperlinking this text to Pres. Trump’s Official Website …
Screenshot Source: https://x.com/elonmusk/status/2008786684058759375?s=20 Grok “Advancing Humanity” “AI For All Humanity” Download the Official Grok app.: “Smartest AI Adviser” Web version links: https://grok.com/ https://x.ai/ Factual 248 Questionable 0
Be a winner in Business & Work Life – Level Up here . . .
MediSkin Clinics
MediSkin Clinics of Dr. Emily P. Soriano, MD, One of the best Dermatologist and Plastic Surgeon in the World, MediSkin Clinics all throughout Davao City, Philippines
MediSkin Clinics of Dr. Emily P. Soriano, MD, One of the best Dermatologist and Plastic Surgeon in the World, MediSkin Clinics all throughout Davao City, Philippines
Mediskin Clinics of Dr. Emily P. Soriano, MD, Surgeon-Dermatologist
Dr. Emily P. Soriano, MD, Best Surgeon-Dermatologist in the World
Best Dermatologist-Plastic Surgeon, Dr. Emily Soriano, MD
Manufactured (By SK Bioscience Co., Ltd. Collaboration with the International Vaccine Institute, GlaxoSmithKline and Coalition for Epidemic Preparedness Innovations), and approved for use in S.Korea. (Link #1 and Link #2)
Says Status is Active but Not Yet Recruiting. Did not specify how many participants from each country but there have been 2 trials made here already. (Link #3)
Results according to GSK: “SK bioscience conducted a Phase III clinical trial in 4,037 adults over 18-year-old across 6 countries (Thailand, Vietnam, New Zealand, Ukraine, the Philippines and South Korea). The vaccine candidate demonstrated superior neutralizing antibody titres over AstraZeneca’s Vaxzevria™ (control vaccine), a currently authorized COVID-19 vaccine. SKYCovione™ vaccine candidate showed a clinically favorable safety profile. …
The results of the Phase III clinical trial show a superior neutralizing antibody response of SKYCovione™ against SARS-CoV-2 parental strain, 2.93 times that of a control vaccine 2 weeks after the second dose.” (link #3)
According to Korea Biomedical Review last Oct.2022 (Independent): (Link #4)
– “Although SK Bioscience argues that the speed of inoculation is getting faster, industry watchers say the company is fighting an uphill battle.”
– No WHO EUL approval yet.
출처 : KBR(https://www.koreabiomed.com)
Any Gain-Of-Function research though? Hmmm … Ukraine + New Zealand + Taiwan + Vietnam … Please, not in my country.
https://clinicaltrials.gov/ct2/show/results/NCT05007951
https://www.gsk.com/en-gb/media/press-releases/sk-bioscience-and-gsk-s-adjuvanted-covid-19-vaccine-candidate-meets-coprimary-objectives-in-a-phase-iii-study/
https://www.koreabiomed.com/news/articleView.html?idxno=14753